Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 2
R&D Momentum
44/100
Pipeline Velocity
6/100
Trial Completion Rate
75/100
Pipeline Concentration
33/100
Pipeline Freshness
60/100
Strategic Signals
Activity
Last 14 days
Maternal Grandmothers in the Born in Guangzhou Cohort Study
Born In Guangzhou Intervention Study
Human Genes and Microbiota in Early Life (HuGME)
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)